Navigation Links
Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
Date:3/31/2008

LONG BEACH, N.Y., March 31 /PRNewswire-FirstCall/ -- Chem Rx Corporation (OTC Bulletin Board: PMQC, PMQCU, PMQCW), a leading provider of institutional pharmacy services, announced today that it has postponed its conference call to review 2007 financial results and discuss 2008 outlook that was originally scheduled for April 1, 2008 at 8:30 a.m. ET. Additional details about the timing of the 2007 financial results press release and corresponding conference call will be forthcoming shortly.

About Chem Rx Corporation

Founded more than 40 years ago, Chem Rx Corporation is a leading provider of institutional pharmacy services in the New York City metropolitan area, as well as parts of New Jersey, upstate New York, and Pennsylvania. Chem Rx's client base includes skilled nursing facilities and a wide range of other long-term care facilities. Through its services, Chem Rx provides more than 65,000 institutional residents with prescription and non-prescription drugs, intravenous medications, durable medical equipment items and surgical supplies. Chem Rx's website address is http://www.chemrx.net.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of Chem Rx's management and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: compliance with government regulations; changes in legislation or regulatory environments; requirements or changes adversely affecting the health care industry, including changes in Medicare reimbursement policies; fluctuations in customer demand; management of rapid growth; intensity of competition; timing, approval and market acceptance of new product introductions and institutional pharmacy locations; general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in Chem Rx's filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. Chem Rx Corporation does not assume any obligation to update the information contained in this press release.

Contacts:

Steven C. Silva

President and Chief Operating Officer

Chem Rx Corporation

516-889-8770

The Ruth Group

Investor Relations

Stephanie Carrington / Jared Hoffman

(646) 536-7017 / 7013

scarrington@theruthgroup.com

jhoffman@theruthgroup.com


'/>"/>
SOURCE Chem Rx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genaera Corporation Announces 2007 Financial Results
2. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
3. Immunosyn Corporation Announces 2007 Results, Files 10KSB
4. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
5. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
6. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
7. Psychemedics Corporation Authorizes A 250,000 Share Stock Repurchase Program
8. Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics
9. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
10. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
11. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
(Date:3/24/2017)... 2017 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ... cancer vaccines, today announced participation at the following conferences: ... Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" ... New York, NY . Agenus will participate ... 9:40 am: Robert B. Stein , M.D., Ph.D., ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):